X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (607) 607
Newsletter (42) 42
Publication (24) 24
Book Review (10) 10
Magazine Article (9) 9
Book Chapter (5) 5
Conference Proceeding (2) 2
Trade Publication Article (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pegaptanib (523) 523
humans (354) 354
ranibizumab (350) 350
ophthalmology (330) 330
index medicus (299) 299
bevacizumab (292) 292
macular degeneration (249) 249
vascular endothelial growth factor a - antagonists & inhibitors (197) 197
female (155) 155
male (155) 155
vascular endothelial growth factor (150) 150
endothelial growth-factor (146) 146
aged (141) 141
age-related macular degeneration (133) 133
pegaptanib sodium (122) 122
angiogenesis inhibitors - therapeutic use (120) 120
macular degeneration - drug therapy (113) 113
antibodies, monoclonal, humanized (107) 107
aptamers, nucleotide - therapeutic use (106) 106
middle aged (106) 106
choroidal neovascularization (101) 101
photodynamic therapy (99) 99
aged, 80 and over (90) 90
intravitreal injections (87) 87
treatment outcome (84) 84
choroidal neovascularization - drug therapy (83) 83
eye diseases (81) 81
angiogenesis inhibitors - administration & dosage (80) 80
verteporfin (79) 79
pharmacology & pharmacy (76) 76
vitreous body (75) 75
injections (74) 74
visual acuity (74) 74
animals (69) 69
neovascularization (67) 67
angiogenesis inhibitors - adverse effects (66) 66
diabetic retinopathy (66) 66
injection (63) 63
vegf (63) 63
antibodies, monoclonal - therapeutic use (60) 60
tomography, optical coherence (60) 60
fluorescein angiography (58) 58
physiological aspects (58) 58
retrospective studies (58) 58
angiogenesis (55) 55
medicine & public health (55) 55
therapy (55) 55
genetic structures (54) 54
diabetic macular edema (53) 53
aflibercept (52) 52
care and treatment (52) 52
prospective studies (52) 52
macular degeneration - complications (51) 51
anti-vegf (50) 50
antibodies, monoclonal - administration & dosage (50) 50
follow-up studies (47) 47
intravitreal injection (47) 47
research (47) 47
triamcinolone (47) 47
safety (46) 46
visual acuity - physiology (46) 46
aptamers, nucleotide - administration & dosage (44) 44
drug therapy (44) 44
intravitreal bevacizumab (44) 44
choroidal neovascularization - etiology (43) 43
macular edema - drug therapy (43) 43
aptamers, nucleotide - adverse effects (41) 41
diabetic retinopathy - drug therapy (41) 41
subfoveal choroidal neovascularization (41) 41
triamcinolone acetonide (41) 41
bevacizumab avastin (40) 40
avastin (38) 38
dosage and administration (38) 38
intravitreal bevacizumab avastin (38) 38
optical coherence tomography (38) 38
analysis (37) 37
sense organs (37) 37
visual acuity - drug effects (37) 37
degeneration (36) 36
edema (35) 35
macular degeneration - physiopathology (35) 35
wet macular degeneration - drug therapy (35) 35
age related macular degeneration (34) 34
glaucoma (34) 34
intraocular pressure (34) 34
intraocular pressure - drug effects (34) 34
retina (34) 34
antibodies, monoclonal - adverse effects (32) 32
adult (31) 31
retinopathy (31) 31
antibodies, monoclonal, humanized - therapeutic use (30) 30
diabetes (30) 30
laser photocoagulation (30) 30
macular edema (30) 30
risk factors (30) 30
angiogenesis inhibitors (28) 28
trial (28) 28
cancer (27) 27
endophthalmitis (27) 27
intellectual property (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (586) 586
German (41) 41
French (10) 10
Turkish (8) 8
Spanish (4) 4
Czech (3) 3
Polish (3) 3
Russian (3) 3
Portuguese (2) 2
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 41, pp. 4853 - 4859
Journal Article
Retina, ISSN 0275-004X, 04/2011, Volume 31, Issue 4, pp. 662 - 668
Purpose: To assess the rate of infectious endophthalmitis and to describe the clinical and microbiological features of eyes that develop clinically suspected... 
VERTEPORFIN | INJECTION | SAFETY | bevacizumab | OPHTHALMOLOGY | endophthalmitis | intravitreal injection | anti-vascular endothelial growth factor | pegaptanib | age-related macular degeneration | ranibizumab
Journal Article
Early Human Development, ISSN 0378-3782, 2012, Volume 88, Issue 12, pp. 937 - 941
Abstract ROP remains a major cause of childhood blindness worldwide. The smallest, sickest infants develop the most severe forms of zone 1 ROP. Such eyes may... 
Advanced Basic Science | Neonatal and Perinatal Medicine | Retinopathy of prematurity (ROP) | Vascular endothelial growth factor inhibitors (anti-VEGF) | “”[pegaptanib, ranibizumab, bevacizumab, aflibercept] | Near confluent laser therapy | Intravitreal injections | ""[pegaptanib, ranibizumab, bevacizumab, aflibercept] | TRIAL | THERAPY | ZONE | INTRAVITREOUS BEVACIZUMAB | INFANTS | PEDIATRICS | Vascular endothelial growth factor inhibitors (anti-VEGF) [pegaptanib, ranibizumab, bevacizumab, aflibercept] | OBSTETRICS & GYNECOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Vascular Endothelial Growth Factors - antagonists & inhibitors | Humans | Recombinant Fusion Proteins - therapeutic use | Aptamers, Nucleotide - therapeutic use | Infant | Aptamers, Nucleotide - adverse effects | Retinopathy of Prematurity - physiopathology | Bevacizumab | Retinopathy of Prematurity - diagnosis | Retinopathy of Prematurity - drug therapy | Infant, Premature | Ranibizumab | Receptors, Vascular Endothelial Growth Factor - adverse effects | Infant, Newborn | Care and treatment | Retrolental fibroplasia | Infants (Premature) | Lasers in surgery | Ophthalmology | Neovascularization | Vascular endothelial growth factor | Index Medicus
Journal Article
Ophthalmology, ISSN 0161-6420, 01/2019, Volume 126, Issue 1, pp. 55 - 63
Purpose: To review the evidence on the safety and efficacy of anti-vascular endothelial growth factor (VEGF) therapies for the treatment of neovascular... 
VEGF-TRAP | TRIALS | COST-EFFECTIVENESS | BEVACIZUMAB | PEGAPTANIB | WET | OPHTHALMOLOGY | VERTEPORFIN PHOTODYNAMIC THERAPY | INTRAOCULAR-PRESSURE | CHOROIDAL NEOVASCULARIZATION | RANIBIZUMAB
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 12, p. e15004
Journal Article
NUCLEIC ACIDS RESEARCH, ISSN 0305-1048, 11/2010, Volume 38, Issue 21, pp. 7822 - 7829
Aptamers are short single-stranded nucleic acids with high affinity to target molecules and are applicable to therapeutics and diagnostics. Regardless of an... 
SYSTEM | CRYSTALLIZATION | REFINEMENT | PROTEIN-A | CAP-DEPENDENT TRANSLATION | PEGAPTANIB | BIOCHEMISTRY & MOLECULAR BIOLOGY | PURIFICATION | MOLECULAR MIMICRY | FC FRAGMENT | SELECTION
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 8, Issue 8, p. CD005139
Journal Article
Angiogenesis, ISSN 0969-6970, 6/2012, Volume 15, Issue 2, pp. 171 - 185
Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis and vascular leak associated with cancers and various eye diseases.... 
Biomedicine | Age-related macular degeneration | Cancer Research | Oncology | Affinity | Ophthalmology | VEGF receptor | Cardiology | Aflibercept | Placental growth factor | Biomedicine general | Cell Biology | ANGIOGENESIS | EFFICACY | MACULAR DEGENERATION | PHASE-II | ANTIBODY | FACTOR THERAPY | EYE | IN-VITRO | PEGAPTANIB | RETINAL DISEASES | PERIPHERAL VASCULAR DISEASE | Angiogenesis Inhibitors - immunology | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor B - antagonists & inhibitors | Recombinant Fusion Proteins - pharmacology | Endothelial Cells - metabolism | Humans | Angiogenesis Inhibitors - pharmacology | Vascular Endothelial Growth Factor B - immunology | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - immunology | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-2 - immunology | Enzyme Activation - drug effects | Bevacizumab | Endothelial Cells - immunology | Vascular Endothelial Growth Factor B - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | HEK293 Cells | Ranibizumab | Vascular Endothelial Growth Factor Receptor-1 - immunology | Antibodies, Monoclonal, Humanized - immunology | Original Paper
Journal Article